Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 1.01, 3.02, 5.02, 5.03, 8.01, 9.01 · 8-K

Research Alliance Corporation III

RACCNASDAQEQUITYCurrent

Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Other Events

Item 1.01. Entry into a Material Definitive Agreement. On May 19, 2026, the Registration Statement on Form S-1 (File No. 333-294549) (the “Registration Statement”) relating to the initial public offering (“IPO”) of Research Alliance Corporation III (the “Company”) was declared effective by the Securities and Exchange Commission.…

Filed May 21, 2026Accepted May 21, 2026, 4:01 PM EDTCIK 2118032Accession 0001193125-26-234382
Share

Company context

We are a newly organized blank check company incorporated on February 19, 2026, as a Cayman Islands exempted company incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, which we refer to throughout this prospectus as our initial business combination. To date, our efforts have been limited to organizational activities as well as activities related to this offering.

Current securities

Recent company filings

  1. SCHEDULE 13G/A - filed by BANK OF AMERICA CORP /DE/ regarding Research Alliance Corp IIIOct 28, 2026
  2. SCHEDULE 13G - filed by Nantahala Capital Management, LLC regarding Research Alliance Corp IIIOct 7, 2026
  3. 425 filingSep 16, 2026
  4. 425 filingSep 11, 2026
  5. S-4 filingAug 24, 2026

Disclosure sections

Items 1.01, 3.02, 5.02, 5.03, 8.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 1.01Item 1.01 - Entry into Material Agreement
Item 1.01. Entry into a Material Definitive Agreement. On May 19, 2026, the Registration Statement on Form S-1 (File No. 333-294549) (the “Registration Statement”) relating to the initial public offering (“IPO”) of Research Alliance Corporation III (the “Company”) was declared effective by the Securities and Exchange Commission. In connection therewith, on May 19, 2026, the Company entered into the following agreements, forms of which were previously filed as exhibits to the Registration Statement: An Underwriting Agreement, dated May 19, 2026, between the Company and Leerink Partners LLC, as sole bookrunning manager of the offering, which contains customary representations and warranties and indemnification of the underwriter by the Company; ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── An Investment Management Trust Agreement, dated May 19, 2026, between the Company and Continental Stock Transfer & Trust Company, which establishes the trust account that will hold the net proceeds of the IPO and certain of the proceeds of the sale of the Private Placement Shares, and sets forth the responsibilities of the trustee; the procedures for withdrawal and direction of funds from the trust account; and indemnification of the trustee by the Company under the agreement; ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── A Registration and Shareholder Rights Agreement, dated May 19, 2026, by and among the Company, Research Alliance Holdings III LLC (the “Sponsor”) and the other parties thereto, which provides for customary demand and piggy-back registration rights for the Sponsor, and customary piggy-back registration rights for certain permitted transferees of the Sponsor; ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── Indemnity Agreements between the Company and each of the officers and directors of the Company, dated May 19, 2026, pursuant to which the Company has agreed to indemnify each officer and director of the Company against certain claims that may arise in their roles as officers and directors of the Company. A form of the Indemnity Agreement is exhibited to this Current Report on Form 8-K as Exhibit 10.4; A Letter Agreement, dated May 19, 2026, by and among the Company, the Sponsor, and each of the officers and directors of the Company, pursuant to which each of the Sponsor and each executive officer and director of the Company has agreed to vote any ordinary shares held by him, her or it in favor of the Company’s initial business combination (subject to the limitations of applicable securities laws); to facilitate the liquidation and winding up of the Company if an initial business combination is not consummated within 24 months of the closing of the IPO; to certain transfer restrictions with respect to the Company’s securities; to certain indemnification obligations of the Sponsor; and the Company has agreed not to enter into a definitive agreement regarding an initial business combination without the prior consent of the Sponsor; ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── A Private Placement Shares Purchase Agreement, dated May 19, 2026, between the Company and the Sponsor, pursuant to which the Sponsor agreed to purchase 275,000 Class A ordinary shares (the “Private Placement Shares”) in a private placement by the Company at a price of $10.00 per Private Placement Share; and An Indemnification Agreement, dated May 19, 2026, between the Company and the Sponsor, pursuant to which the Company has agreed to indemnify the Sponsor and its affiliates, including RA Capital Management, L.P., from certain liabilities arising in connection with the Company’s affairs. ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── On May 21, 2026, the Company consummated the IPO of 7,500,000 Class A ordinary shares (the “Public Shares”). The Public Shares were sold at an offering price of $10.00 per Public Share, generating gross proceeds of $75,000,000 (before underwriting discounts and commission and offering expenses). As of May 21, 2026, a total of $75,000,000 of the net proceeds from the IPO and the Private Placement (including the underwriter’s deferred commission of $2,250,000) were deposited in a trust account established for the benefit of the Company’s public shareholders, with Continental Stock Transfer & Trust Company acting as trustee. An audited balance sheet as of May 21, 2026 reflecting receipt of the proceeds upon consummation of the IPO and the Private Placement will be filed within 4 business days of the consummation of the IPO. The above descriptions are qualified in their entirety by reference to the full text of the applicable agreement, each of which is incorporated by reference herein and attached hereto as Exhibits 1.1, 4.1, 10.1, 10.2, 10.3, 10.4 and 10.5, respectively.
Item 3.02Item 3.02 - Unregistered Sales of Equity
Item 3.02. Unregistered Sales of Equity Securities. Simultaneously with the closing of the IPO, the Company consummated the private placement (“Private Placement”) of 275,000 Private Placement Shares with the Sponsor at a price of $10.00 per Private Placement Share, generating total proceeds of $2,750,000. The Private Placement Shares are identical to the Public Shares, being Class A ordinary shares, sold in the IPO except with respect to certain registration rights and transfer restrictions. Additionally, the holders of the Private Placement Shares have agreed to certain restrictions on the Private Placement Shares, as described in the Registration Statement. Such holders agreed not to transfer, assign or sell any of the Private Placement Shares (except in limited circumstances, as described in the Registration Statement) until 30 days after the completion of the Company’s initial business combination. The holders were granted certain demand and piggyback registration rights in connection with the purchase of the Private Placement Shares. The Private Placement Shares were issued pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, as the transaction did not involve a public offering.
Item 5.02Item 5.02 - Departure/Election of Directors
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On May 19, 2026, and in connection with the IPO, Michael F. MacLean and Timothy J. Miller were appointed to the board of directors of the Company (the “Board”). Effective May 19, 2026, (i) each of Mr. MacLean and Mr. Miller was appointed to the Board’s Audit Committee, with Mr. MacLean serving as its chair; (ii) each of Matthew Hammond, Mr. MacLean, and Mr. Miller was appointed to the Board’s Nominating Committee, with Mr. Miller serving as its chair; and (iii) each of Mr. MacLean and Mr. Miller was appointed to the Board’s Compensation Committee, with Mr. Miller serving as its chair. In March 2026, the Sponsor transferred 30,000 Class B ordinary shares of the Company, par value $0.0001 per share (“Class B ordinary shares”), to each of Mr. MacLean and Mr. Miller as compensation for his service as a director of the Company. In May 2026, in connection with a share capitalization effected to maintain the initial shareholders’ ownership at 15% of the issued and outstanding ordinary shares (excluding the Private Placement Shares) upon consummation of the IPO, an additional 9,130 Class B ordinary shares were issued to each of Mr. MacLean and Mr. Miller, resulting in each of Mr. MacLean and Mr. Miller holding 39,130 Class B ordinary shares. Other than the foregoing, none of the directors is party to any arrangement or understanding with any person pursuant to which they were appointed as directors, nor is any director party to any transaction required to be disclosed under Item 404(a) of Regulation S-K involving the Company.
Item 5.03Item 5.03 - Amendments to Articles/Bylaws
Item 5.03. Amendments to Certificate of Incorporation or Bylaws; Change in Fiscal Year. On May 19, 2026, and in connection with the IPO, the Company adopted its Amended and Restated Memorandum and Articles of Association. The Amended and Restated Memorandum and Articles of Association is filed herewith as Exhibit 3.1 and is incorporated by reference herein.
Item 8.01Item 8.01 - Other Events
Item 8.01. Other Events. On May 19, 2026, the Company issued a press release announcing the pricing of the IPO, a copy of which is attached as Exhibit 99.1 to this Current Report on Form 8-K.
Filed exhibits (1)
EX-99.1 (by filename) d128014dex991.htm

Exhibit 99.1 RESEARCH ALLIANCE CORPORATION III ANNOUNCES PRICING OF $75 MILLION INITIAL PUBLIC OFFERING NEW YORK, May 19, 2026 - Research Alliance Corporation III (the “Company”), a special purpose acquisition company, announced today the pricing of its initial public offering of 7,500,000 Class A ordinary shares at $10.00 per share. The shares will be listed on the Nasdaq Capital Market and trade under the ticker symbol “RACC” beginning May 20, 2026. The Company expects the offering to close on May 21, 2026, subject to customary closing conditions. The Company, sponsored by an affiliate of RA Capital Management, L.P., is led by CEO Matthew Hammond, PhD, MBA and CBO/COO Henry Stusnick. The Company is a blank check company incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. The Company may pursue an initial business combination in any business, industry, sector or geographical location, but the Company intends to focus its search on a target business in the healthcare or healthcare-related industries, where it believes the expertise of its ma…

Open exhibit ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.